Loading...
Docoh
Log in Free sign up

Diffusion Pharmaceuticals (DFFN)

Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most. Diffusion's lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine's most intractable and difficult-to-treat conditions. In addition to TSC, Diffusion's product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage development.

Company profile

Ticker
DFFN
Exchange
NASDAQ
Website
www.diffusionpharma.com
CEO
Robert J. Cobuzzi
Employees
Incorporated
Delaware
Location
Virginia
Fiscal year end
Dec 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie ...
Former names
FERIS INTERNATIONAL, INC., RestorGenex Corp, Stratus Media Group, Inc, TITAN MOTORCYCLE CO OF AMERICA INC
SEC CIK
0001053691
Corporate docs
Subsidiaries
Canterbury Laboratories, LLC • Hygeia Therapeutics, Inc. • Diffusion Pharmaceuticals LLC ...
IRS number
300645032

DFFN stock data

News

From Benzinga Pro
Diffusion Pharmaceuticals To Initiate Phase 2 Trial In Patients With Glioblastoma Multiforme Incorporating Innovative Imaging Methodology To Evaluate Tumor Oxygenation
26 Jul 22
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”)
Diffusion Pharmaceuticals Announces Effects In Altitude Trial
23 Jun 22
Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise interval Positive effects on post-exercise recovery based when comparing measurements 10 min post-exercise to
DFFN: Data from Altitude Trial Expected in June 2022…
25 May 22
By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT

Press releases

From Benzinga Pro
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
11 Aug 22
• Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022• Reported Positive Effects in TSC Altitude Trial• Ended Quarter with $28.5 million in Cash, Cash Equivalents and Marketable
Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation
26 Jul 22
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate ("TSC") in newly diagnosed glioblastoma multiforme ("GBM") patientsCompany to evaluate
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
23 Jun 22
Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise intervalPositive effects on post-exercise recovery based when comparing measurements 10 min post-exercise to measurements at the
Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer
18 May 22
Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
17 May 22

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

11 Aug 22
12 Aug 22
31 Dec 22

Financial summary

Financial statements Chart DFFN financial data
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 5.97M 5.97M 5.97M 5.97M 5.97M 5.97M
Cash burn (monthly) 1.3M 3.11M 1.42M 2.08M 1.34M 1.23M
Cash used (since last report) 1.89M 4.52M 2.05M 3.02M 1.94M 1.78M
Cash remaining 4.08M 1.45M 3.91M 2.95M 4.03M 4.18M
Runway (months of cash) 3.1 0.5 2.8 1.4 3.0 3.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

DFFN insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Aug 22 Cobuzzi Robert Joseph Jr. Common Stock Sale back to company Dispose D No No 0 121 0 1,204
1 Aug 22 Cobuzzi Robert Joseph Jr. Common Stock Option exercise Acquire M No No 0 327 0 1,325
1 Aug 22 Cobuzzi Robert Joseph Jr. RSU Common Stock Option exercise Dispose M No No 0 327 0 654
31 May 22 Jane H Hollingsworth Common Stock Sale back to company Dispose D No No 0 67 0 771
31 May 22 Jane H Hollingsworth Common Stock Option exercise Acquire M No No 0 183 0 838
31 May 22 Jane H Hollingsworth RSU Common Stock Option exercise Dispose M No No 0 183 0 915
2 May 22 Cobuzzi Robert Joseph Jr. Common Sock Sale back to company Dispose D No No 0 121 0 998
2 May 22 Cobuzzi Robert Joseph Jr. Common Stock Option exercise Acquire M No No 0 327 0 1,119
2 May 22 Cobuzzi Robert Joseph Jr. RSU Common Stock Option exercise Dispose M No No 0 327 0 981
18 Apr 22 Cobuzzi Robert Joseph Jr. Common Stock Conversion Acquire C No No 25 100 2.5K 792
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

DFFN institutional ownership history Ownership history
13F holders Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio – – –
Largest owners Shares Value Change
Largest transactions Shares Bought/sold Change
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Curis • Hemoglobin Oxygen Therapeutics

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: acid, acidity, adjuvant, affirmed, agent, aggressive, arterial, ascent, BTIG, cellular, concomitant, core, crossover, deadly, endeavor, escalation, experimental, feet, fulfill, imaging, Instruction, investigate, investigated, July, lactate, lactic, LLC, magnetic, malignant, metabolic, Methodology, notable, partnership, percent, PET, ph, population, preserve, reinforce, resonance, respiratory, rest, risky, sea, stressful, structure, suffering, survival, temozolomide, type, ultimate, wash, week, winding
Removed: base, cancer, half, improve, pathway, portion, reduce, Section, topline
From filing 10-Q 2022 Q2
Financial reports
View all
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
18 Mar 22
10-Q
2021 Q3
Quarterly report
10 Nov 21
10-Q
2021 Q2
Quarterly report
11 Aug 21
10-Q
2021 Q1
Quarterly report
7 May 21
10-K
2020 FY
Annual report
16 Mar 21
10-Q
2020 Q3
Quarterly report
12 Nov 20
10-Q
2020 Q2
Quarterly report
7 Aug 20
10-Q
2020 Q1
Quarterly report
11 May 20
Current reports
View all
8-K
Other Events
27 Jul 22
8-K
Entry into a Material Definitive Agreement
22 Jul 22
8-K
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
28 Jun 22
8-K
Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer
23 May 22
8-K
Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
15 May 22
8-K
Other Events
4 May 22
8-K
Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan
18 Apr 22
8-K
Diffusion Pharmaceuticals Completes Dosing in Altitude Trial
12 Apr 22
8-K
Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders
8 Apr 22
8-K
Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update
21 Mar 22
Registration and prospectus
View all
S-8
Registration of securities for employees
12 Aug 22
424B5
Prospectus supplement for primary offering
22 Jul 22
S-8
Registration of securities for employees
12 Aug 21
424B5
Prospectus supplement for primary offering
16 Feb 21
FWP
Free writing prospectus
11 Feb 21
FWP
Free writing prospectus
11 Feb 21
424B5
Prospectus supplement for primary offering
11 Feb 21
424B2
Prospectus for primary offering
2 Oct 20
S-3
Shelf registration
25 Sep 20
424B3
Prospectus supplement
8 Jun 20
Proxies
View all
DEFA14A
Additional proxy soliciting materials
8 Apr 22
DEFA14A
Additional proxy soliciting materials
30 Mar 22
DEF 14A
Definitive proxy
28 Mar 22
PRE 14A
Preliminary proxy
18 Mar 22
DEF 14A
Definitive proxy
28 Feb 22
PRE 14A
Preliminary proxy
18 Feb 22
DEFA14A
Additional proxy soliciting materials
21 Jun 21
DEFA14A
Additional proxy soliciting materials
20 May 21
DEF 14A
Definitive proxy
29 Apr 21
DEFA14A
Additional proxy soliciting materials
29 Apr 20
Other
View all
EFFECT
Notice of effectiveness
5 Oct 20
CORRESP
Correspondence with SEC
29 Sep 20
UPLOAD
Letter from SEC
28 Sep 20
EFFECT
Notice of effectiveness
11 Jun 20
CORRESP
Correspondence with SEC
2 Jun 20
UPLOAD
Letter from SEC
1 Jun 20
EFFECT
Notice of effectiveness
30 Dec 19
CORRESP
Correspondence with SEC
22 Dec 19
UPLOAD
Letter from SEC
22 Dec 19
EFFECT
Notice of effectiveness
14 Nov 19
Ownership
View all
4
Diffusion Pharmaceuticals / Robert Joseph Jr. Cobuzzi ownership change
3 Aug 22
4
Diffusion Pharmaceuticals / Jane H Hollingsworth ownership change
2 Jun 22
4
Diffusion Pharmaceuticals / Robert Joseph Jr. Cobuzzi ownership change
3 May 22
4
Diffusion Pharmaceuticals / Robert Joseph Jr. Cobuzzi ownership change
19 Apr 22
4
Diffusion Pharmaceuticals / WILLIAM ROBERT ELDER ownership change
19 Apr 22
4
Diffusion Pharmaceuticals / WILLIAM ROBERT ELDER ownership change
22 Mar 22
4
Diffusion Pharmaceuticals / Robert Joseph Jr. Cobuzzi ownership change
22 Mar 22
4/A
Diffusion Pharmaceuticals / Robert Joseph Jr. Cobuzzi ownership change
2 Feb 22
4
Diffusion Pharmaceuticals / Robert Joseph Jr. Cobuzzi ownership change
2 Feb 22
4
Diffusion Pharmaceuticals / William Karl Hornung ownership change
31 Jan 22

Patents

Utility
Trans carotenoids, their synthesis, formulation and uses
22 Mar 22
The invention relates to trans carotenoid compounds and salts thereof as well as compositions thereof, methods for making them, and uses thereof.
Utility
Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
30 Nov 21
The subject disclosure relates to compounds and compositions including chemotherapy agents and/or radiation therapy with bipolar trans carotenoids, and the use of such compounds for the treatment of various cancers including pancreatic and brain cancers.
Utility
Diffusion enhancing compounds and their use alone or with thrombolytics
19 Oct 21
The subject invention relates to diffusion enhancing compounds and their use alone or with thrombolytic agents for the treatment of disorders resulting from the formation of a thrombus such as a myocardial infarction or stroke.
Utility
Diffusion Enhancing Compounds and Their Use with Thrombectomy and Embolectomy and Other Vascular Disease Procedures
12 Aug 21
The subject invention relates to novel methods for the rapid treatment of disorders resulting from thrombosis or embolism such as a myocardial infraction or stroke.

Reddit threads

View all